Glimepiride - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (3)Enzymes (1)

Targets (3)Enzymes (1)Biointeractions (4)

Identification

Name

Glimepiride

Accession Number

DB00222 (APRD00381)

Type

Small Molecule

Groups

Approved

Description

Glimepiride is the first III generation sulphonyl urea it is a very potent sulphonyl urea with long duration of action.

Structure

MOL SDF PDB SMILES InChI

Synonyms

Glimepirida

Glimépiride

Glimepiridum

External IDs

HOE 490 / HOE-490

Product Ingredients

Not Available

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Amaryl	Tablet	1 mg	Oral	Sanofi Aventis	2002-03-12	Not applicable	Canada
Amaryl	Tablet	4 mg/1	Oral	Sanofi Aventis	2009-06-18	Not applicable	US
Amaryl	Tablet	2 mg	Oral	Sanofi Aventis	2002-03-12	Not applicable	Canada
Amaryl	Tablet	1 mg/1	Oral	Sanofi Aventis	2009-06-18	Not applicable	US
Amaryl	Tablet	2 mg/1	Oral	Sanofi Aventis	2009-06-18	Not applicable	US
Amaryl	Tablet	4 mg	Oral	Sanofi Aventis	2002-03-12	Not applicable	Canada
Co Glimepiride	Tablet	4 mg	Oral	Cobalt Laboratories	2006-04-24	2012-08-02	Canada
Co Glimepiride	Tablet	1 mg	Oral	Cobalt Laboratories	2006-04-24	2012-08-02	Canada
Co Glimepiride	Tablet	2 mg	Oral	Cobalt Laboratories	2006-04-24	2012-08-02	Canada
Novo-glimepiride	Tablet	4 mg	Oral	Novopharm Limited	2006-03-08	2015-10-26	Canada
Novo-glimepiride	Tablet	2 mg	Oral	Novopharm Limited	2006-03-08	2015-10-26	Canada
Novo-glimepiride	Tablet	1 mg	Oral	Novopharm Limited	2006-03-08	2015-10-26	Canada
PMS-glimepiride	Tablet	4 mg	Oral	Pharmascience Inc	Not applicable	Not applicable	Canada
PMS-glimepiride	Tablet	1 mg	Oral	Pharmascience Inc	2006-08-15	2016-10-28	Canada
PMS-glimepiride	Tablet	2 mg	Oral	Pharmascience Inc	2006-08-15	2016-10-28	Canada
Ratio-glimepiride	Tablet	2 mg	Oral	Teva	2005-11-22	2017-04-04	Canada
Ratio-glimepiride	Tablet	4 mg	Oral	Teva	2005-11-22	2017-04-04	Canada
Ratio-glimepiride	Tablet	1 mg	Oral	Teva	2005-11-22	2017-04-04	Canada
Sandoz Glimepiride	Tablet	1 mg	Oral	Sandoz Canada Incorporated	2005-08-04	Not applicable	Canada
Sandoz Glimepiride	Tablet	3 mg	Oral	Sandoz Canada Incorporated	Not applicable	Not applicable	Canada
Sandoz Glimepiride	Tablet	2 mg	Oral	Sandoz Canada Incorporated	2005-08-04	Not applicable	Canada
Sandoz Glimepiride	Tablet	4 mg	Oral	Sandoz Canada Incorporated	2005-08-04	Not applicable	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-glimepiride	Tablet	2 mg	Oral	Apotex Corporation	2007-09-29	Not applicable	Canada
Apo-glimepiride	Tablet	4 mg	Oral	Apotex Corporation	2007-09-29	Not applicable	Canada
Apo-glimepiride	Tablet	1 mg	Oral	Apotex Corporation	2007-09-29	Not applicable	Canada
Glimepiride	Tablet	2 mg/1	Oral	Golden State Medical Supply	2009-08-17	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Red Pharm Drug, Inc.	2007-08-23	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Bionpharma Inc.	2015-10-01	Not applicable	US
Glimepiride	Tablet	3 mg/1	Oral	Micro Labs Limited	2013-06-13	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Northwind Pharmaceuticals	2015-02-04	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2005-10-06	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	A S Medication Solutions	2005-10-06	2017-06-20	US
Glimepiride	Tablet	1 mg/1	Oral	bryant ranch prepack	2007-08-23	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Remedy Repack	2015-03-16	2017-04-14	US
Glimepiride	Tablet	2 mg/1	Oral	Remedy Repack	2015-11-12	2016-10-13	US
Glimepiride	Tablet	2 mg/1	Oral	Aidarex Pharmaceuticals LLC	2013-06-13	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	A S Medication Solutions	2007-08-23	2017-06-20	US
Glimepiride	Tablet	1 mg/1	Oral	Remedy Repack	2013-11-12	2016-12-24	US
Glimepiride	Tablet	1 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2015-10-01	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2007-08-23	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	International Laboratories, Llc	2009-02-06	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Amerincan Health Packaging	2014-07-30	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Clinical Solutions Wholsesale	2005-10-06	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Stat Rx USA	2005-10-06	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Aurobindo Pharma	2012-06-29	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	A S Medication Solutions	2007-08-23	2017-06-20	US
Glimepiride	Tablet	1 mg/1	Oral	Citron Pharma LLC	2012-06-29	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	St. Marys Medical Park Pharmacy	2013-05-09	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Mylan Pharmaceuticals	2006-03-01	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Solco healthcare U.S., LLC	2017-01-30	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Proficient Rx LP	2007-08-23	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Physicians Total Care, Inc.	2005-10-20	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2015-07-14	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Teva	2005-10-06	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Red Pharm Drug, Inc.	2007-08-23	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Bionpharma Inc.	2015-10-01	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Dr Reddy's Laboratories	2005-10-06	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Perrigo New York Inc.	2005-10-06	2017-01-18	US
Glimepiride	Tablet	2 mg/1	Oral	Liberty Pharmaceuticals, Inc.	2012-01-01	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Qualitest	2010-10-14	2018-09-22	US
Glimepiride	Tablet	2 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-11-03	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Carlsbad Technology, Inc.	2012-01-01	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Accord Healthcare Limited	2007-08-23	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	International Laboratories, Llc	2009-02-06	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2007-08-23	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Virtus Pharmaceuticals	2015-07-14	Not applicable	US
Glimepiride	Tablet	8 mg/1	Oral	Micro Labs Limited	2013-06-13	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Remedy Repack	2013-05-14	2017-01-18	US
Glimepiride	Tablet	2 mg/1	Oral	Blenheim Pharmacal, Inc.	2013-10-08	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	A S Medication Solutions	2007-08-23	2017-06-20	US
Glimepiride	Tablet	2 mg/1	Oral	Clinical Solutions Wholsesale	2005-10-06	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Aurobindo Pharma	2012-06-29	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Proficient Rx LP	2007-08-23	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Directrx	2016-02-04	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Stat Rx USA	2005-10-06	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Virtus Pharmaceuticals	2013-12-15	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Rebel Distributors	2005-10-06	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Amerincan Health Packaging	2009-05-12	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Unit Dose Services	2007-08-23	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	St. Marys Medical Park Pharmacy	2014-05-23	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Cardinal Health	2010-11-04	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	bryant ranch prepack	2005-10-06	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2005-10-06	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Micro Labs Limited	2013-06-13	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Mylan Institutional	2006-03-27	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2012-01-01	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Blue Point Laboratories	2014-02-26	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Unit Dose Services	2005-10-06	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Qualitest	2010-10-14	2018-09-22	US
Glimepiride	Tablet	2 mg/1	Oral	Citron Pharma LLC	2012-06-29	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Carlsbad Technology, Inc.	2012-01-01	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Mylan Pharmaceuticals	2006-03-01	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Solco healthcare U.S., LLC	2017-01-30	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Golden State Medical Supply	2009-08-17	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	bryant ranch prepack	2005-10-06	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Virtus Pharmaceuticals	2015-07-14	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Micro Labs Limited	2013-06-13	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Northwind Pharmaceuticals	2014-12-29	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2005-10-06	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	A S Medication Solutions	2010-10-14	2017-06-20	US
Glimepiride	Tablet	4 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2005-10-06	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Remedy Repack	2015-06-04	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Directrx	2015-11-24	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Aidarex Pharmaceuticals LLC	2005-10-06	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	A S Medication Solutions	2007-08-23	2017-06-20	US
Glimepiride	Tablet	1 mg/1	Oral	Physicians Total Care, Inc.	2005-10-20	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Northwind Pharmaceuticals	2017-02-24	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Teva	2005-10-06	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	International Laboratories, Llc	2009-02-06	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Avera Mc Kennan Hospital	2015-04-21	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Dr Reddy's Laboratories	2005-10-06	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2005-10-06	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Remedy Repack	2016-01-25	2017-03-03	US
Glimepiride	Tablet	2 mg/1	Oral	bryant ranch prepack	2005-10-06	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-06-10	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Cardinal Health	2007-08-23	2017-04-25	US
Glimepiride	Tablet	1 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2007-08-23	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	A S Medication Solutions	2012-01-01	2017-06-20	US
Glimepiride	Tablet	1 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2015-07-14	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Aidarex Pharmaceuticals LLC	2007-08-23	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Perrigo New York Inc.	2005-10-06	2017-01-18	US
Glimepiride	Tablet	4 mg/1	Oral	Liberty Pharmaceuticals, Inc.	2012-01-01	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Remedy Repack	2016-11-04	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Accord Healthcare Limited	2007-08-23	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Virtus Pharmaceuticals	2013-12-15	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Blenheim Pharmacal, Inc.	2013-10-08	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Blue Point Laboratories	2014-02-26	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Unit Dose Services	2005-10-06	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Rebel Distributors	2005-10-06	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Amerincan Health Packaging	2009-05-12	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Unit Dose Services	2007-08-23	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	St. Marys Medical Park Pharmacy	2013-05-09	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Remedy Repack	2015-07-17	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Golden State Medical Supply	2009-08-17	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2005-10-06	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Micro Labs Limited	2013-06-13	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Mylan Institutional	2006-03-27	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2012-01-01	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Teva	2005-10-06	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Aidarex Pharmaceuticals LLC	2015-10-01	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Bionpharma Inc.	2015-10-01	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Dr Reddy's Laboratories	2005-10-06	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2007-08-23	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Liberty Pharmaceuticals, Inc.	2012-01-01	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Qualitest	2010-10-14	2018-04-30	US
Glimepiride	Tablet	4 mg/1	Oral	Citron Pharma LLC	2012-06-29	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Carlsbad Technology, Inc.	2012-01-01	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Mylan Pharmaceuticals	2006-03-01	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Solco healthcare U.S., LLC	2017-01-30	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	bryant ranch prepack	2005-10-06	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Virtus Pharmaceuticals	2015-07-14	Not applicable	US
Glimepiride	Tablet	6 mg/1	Oral	Micro Labs Limited	2013-06-13	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Remedy Repack	2013-05-15	2017-01-18	US
Glimepiride	Tablet	1 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2005-10-06	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	A S Medication Solutions	2005-10-06	2017-06-20	US
Glimepiride	Tablet	4 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-11-17	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Aurobindo Pharma	2012-06-29	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Directrx	2015-01-01	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Proficient Rx LP	2007-08-23	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2005-10-06	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Remedy Repack	2016-07-13	2017-02-15	US
Glimepiride	Tablet	4 mg/1	Oral	Physicians Total Care, Inc.	2005-10-19	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Remedy Repack	2017-03-08	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Med Vantx, Inc.	2012-04-19	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-07-11	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Cardinal Health	2007-08-23	2017-04-25	US
Glimepiride	Tablet	1 mg/1	Oral	Unit Dose Services	2005-10-06	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	A S Medication Solutions	2012-01-01	2017-06-20	US
Glimepiride	Tablet	1 mg/1	Oral	bryant ranch prepack	2005-10-06	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2007-08-23	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Perrigo New York Inc.	2005-10-06	2017-01-18	US
Glimepiride	Tablet	1 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2012-01-01	Not applicable	US
Glimepiride	Tablet	1 mg/1	Oral	Blue Point Laboratories	2014-02-26	Not applicable	US
Glimepiride	Tablet	4 mg/1	Oral	Accord Healthcare Limited	2007-08-23	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Virtus Pharmaceuticals	2013-12-15	Not applicable	US
Glimepiride	Tablet	2 mg/1	Oral	Rebel Distributors	2005-10-06	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
GLIMPID	Ranbaxy Laboratories
GLIMY	Dr.Reddy's Labs

Brand mixtures

Name	Labeller	Ingredients
Avaglim	Smith Kline Beecham	Glimepiride Rosiglitazone
Avandaryl	Glaxosmithkline Inc	Glimepiride Rosiglitazone
Duetact	Takeda	Glimepiride Pioglitazone
Pioglitazone and Glimepiride	Prasco, Laboratories	Glimepiride Pioglitazone
Pioglitazone Hydrochloride and Glimepiride	Sandoz	Glimepiride Pioglitazone
Tandemact	Takeda Pharma A/S	Glimepiride Pioglitazone

Categories

UNII

6KY687524K

CAS number

93479-97-1

Weight

Average: 490.62
Monoisotopic: 490.224991385

Chemical Formula

C₂₄H₃₄N₄O₅S

InChI Key

WIGIZIANZCJQQY-RUCARUNLSA-N

InChI

InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

IUPAC Name

3-ethyl-4-methyl-2-oxo-N-(2-{4-[({[(1r,4r)-4-methylcyclohexyl]-C-hydroxycarbonimidoyl}amino)sulfonyl]phenyl}ethyl)-2,5-dihydro-1H-pyrrole-1-carboximidic acid

SMILES

[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1

Pharmacology

Indication

For concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.

Structured Indications

Type 2 Diabetes Mellitus

Pharmacodynamics

Glimepiride, like glyburide and glipizide, is a "second-generation" sulfonylurea agents. Glimepiride is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin.

Mechanism of action

The mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glimepiride likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
ATP-sensitive inward rectifier potassium channel 11	Protein	yes	inhibitor	Human	Q14654	details
ATP-sensitive inward rectifier potassium channel 1	Protein	yes	inhibitor	Human	P48048	details
ATP-binding cassette sub-family C member 8	Protein	yes	inducer	Human	Q09428	details

Absorption

Completely (100%) absorbed following oral administration.

Volume of distribution

21.8 ± 13.9 L [Volunteers]
19.8 ± 12.7 L [Patients with Type 2 diabetes, Single Dose]
37.1 ± 18.2 L [Patients with Type 2 diabetes, Multiple Dose]

Protein binding

Over 99.5% bound to plasma protein.

Metabolism

Hepatic. Following either an intravenous or oral dose, glimepiride is completely metabolized by oxidative biotransformation to a major metabolite, cyclohexyl hydroxymethyl derivative (M1), via the hepatic cytochrome P450 II C9 subsystem. M1 is further metabolized to the carboxyl derivative (M2) by one or several cytosolic enzymes. M1, but not M2, possessed approximately one third of the pharmacologic activity of its parent in an animal model. However, whether the glucose-lowering effect of M1 is clinically significant is not clear.

Substrate	Enzymes	Product
Glimepiride	Cytochrome P450 2C9	Cyclohexyl hydroxymethyl glimepiride	Details
Cyclohexyl hydroxymethyl glimepiride	Alcohol dehydrogenase [NADP(+)]	Cyclohexyl carboxyl glimepiride	Details

Route of elimination

Not Available

Half life

Approximately 5 hours following single dose.

Clearance

52.1 +/- 16.0 mL/min [Normal subjects with single oral dose]
48.5 +/- 29.3 mL/min [Patients with Type 2 diabetes, with single oral dose]
52.7 +/- 40.3 mL/min [Patients with Type 2 diabetes, with multiple oral dose]
47.8 mL/min [healthy after intravenous (IV) dosing]

Toxicity

Severe hypoglycemic reactions with coma, seizure, or other neurological impairment.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
Glucose-6-phosphate 1-dehydrogenase	Villeurbanne	Not Available	1000_1002delACC	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Torun	Not Available	1006A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Sunderland	Not Available	105_107delCAT	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Iwatsuki	Not Available	1081G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Serres	Not Available	1082C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Tondela	Not Available	1084_1101delCTGAACGAGCGCAAGGCC	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Loma Linda	Not Available	1089C->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Aachen	Not Available	1089C->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Tenri	Not Available	1096A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Montpellier	Not Available	1132G>A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Calvo Mackenna	Not Available	1138A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Riley	Not Available	1139T->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Olomouc	Not Available	1141T->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Tomah	Not Available	1153T->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Lynwood	Not Available	1154G->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Madrid	Not Available	1155C->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Iowa, Walter Reed, Springfield	Not Available	1156A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Beverly Hills, Genova, Iwate, Niigata, Yamaguchi	Not Available	1160G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Hartford	Not Available	1162A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Praha	Not Available	1166A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Krakow	Not Available	1175T>C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Wisconsin	Not Available	1177C->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Nashville, Anaheim, Portici	Not Available	1178G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Alhambra	Not Available	1180G->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Bari	Not Available	1187C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Puerto Limon	Not Available	1192G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Covao do Lobo	Not Available	1205C>A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Clinic	Not Available	1215G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Utrecht	Not Available	1225C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Suwalki	Not Available	1226C->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Riverside	Not Available	1228G->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Japan, Shinagawa	Not Available	1229G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Kawasaki	Not Available	1229G->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Munich	Not Available	1231A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Georgia	Not Available	1284C->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Sumare	Not Available	1292T->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Telti/Kobe	Not Available	1318C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Santiago de Cuba, Morioka	Not Available	1339G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Harima	Not Available	1358T->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Figuera da Foz	Not Available	1366G->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Amiens	Not Available	1367A>T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Bangkok Noi	Not Available	1376G->T, 1502T->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Fukaya	Not Available	1462G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Campinas	Not Available	1463G->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Buenos Aires	Not Available	1465C>T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Arakawa	Not Available	1466C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Brighton	Not Available	1488_1490delGAA	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Kozukata	Not Available	159G->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Amsterdam	Not Available	180_182delTCT	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	No name	Not Available	202G->A, 376A->G, 1264C>G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Swansea	Not Available	224T->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Urayasu	Not Available	281_283delAGA	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Vancouver	Not Available	317C->G544C->T592C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Mt Sinai	Not Available	376A->G, 1159C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Plymouth	Not Available	488G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Volendam	Not Available	514C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Shinshu	Not Available	527A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Chikugo	Not Available	535A->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Tsukui	Not Available	561_563delCTC	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Pedoplis-Ckaro	Not Available	573C>G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Santiago	Not Available	593G->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Minnesota, Marion, Gastonia, LeJeune	Not Available	637G->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Cincinnati	Not Available	637G->T, 1037A->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Harilaou	Not Available	648T->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	North Dallas	Not Available	683_685delACA	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Asahikawa	Not Available	695G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Durham	Not Available	713A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Stonybrook	Not Available	724_729delGGCACT	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Wayne	Not Available	769C->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Aveiro	Not Available	806G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Cleveland Corum	Not Available	820G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Lille	Not Available	821A>T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Bangkok	Not Available	825G>C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Sugao	Not Available	826C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	La Jolla	Not Available	832T->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Wexham	Not Available	833C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Piotrkow	Not Available	851T>C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	West Virginia	Not Available	910G->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Omiya	Not Available	921G->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Nara	Not Available	953_976delCCACCAAAGGGTACCTGGAC GACC	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Manhattan	Not Available	962G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Rehevot	Not Available	964T->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Honiara	Not Available	99A->G / 1360C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Tokyo, Fukushima	Not Available	1246G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Chatham	Not Available	1003G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Fushan	Not Available	1004C->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Partenope	Not Available	1052G->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Ierapetra	Not Available	1057C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Anadia	Not Available	1193A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Abeno	Not Available	1220A->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Surabaya	Not Available	1291G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Pawnee	Not Available	1316G->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	S. Antioco	Not Available	1342A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Cassano	Not Available	1347G->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Hermoupolis	Not Available	1347G->C / 1360C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Union,Maewo, Chinese-2, Kalo	Not Available	1360C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Andalus	Not Available	1361G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Cosenza	Not Available	1376G->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Canton, Taiwan- Hakka, Gifu-like, Agrigento-like	Not Available	1376G->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Flores	Not Available	1387C->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Kaiping, Anant, Dhon, Sapporo-like, Wosera	Not Available	1388G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Kamogawa	Not Available	169C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Costanzo	Not Available	179T>C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Amazonia	Not Available	185C->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Songklanagarind	Not Available	196T->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Hechi	Not Available	202G->A / 871G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Namouru	Not Available	208T->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Bao Loc	Not Available	352T>C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Crispim	Not Available	375G->T, 379G->T383T->C384C>T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Acrokorinthos	Not Available	376A->G / 463C->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Santa Maria	Not Available	376A->G / 542A->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Ananindeua	Not Available	376A->G / 871G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Vanua Lava	Not Available	383T->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Valladolid	Not Available	406C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Belem	Not Available	409C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Liuzhou	Not Available	442G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Shenzen	Not Available	473G>A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Taipei ‚ÄúChinese- 3‚Äù	Not Available	493A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Toledo	Not Available	496C>T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Naone	Not Available	497G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Nankang	Not Available	517T->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Miaoli	Not Available	519C->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Mediterranean, Dallas, Panama‚ Sassari, Cagliari, Birmingham	Not Available	563C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Coimbra Shunde	Not Available	592C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Nilgiri	Not Available	593G>A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Radlowo	Not Available	679C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Roubaix	Not Available	811G>C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Haikou	Not Available	835A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Chinese-1	Not Available	835A->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Mizushima	Not Available	848A>G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Osaka	Not Available	853C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Viangchan, Jammu	Not Available	871G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Seoul	Not Available	916G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Ludhiana	Not Available	929G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Farroupilha	Not Available	977C->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Chinese-5	Not Available	1024C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Rignano	Not Available	130G>A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Orissa	Not Available	131C->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	G6PDNice	Not Available	1380G>C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Kamiube, Keelung	Not Available	1387C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Neapolis	Not Available	1400C->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Aures	Not Available	143T->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Split	Not Available	1442C->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Kambos	Not Available	148C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Palestrina	Not Available	170G>A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Metaponto	Not Available	172G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Musashino	Not Available	185C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Asahi	Not Available	202G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	A- (202), Ferrara I	Not Available	202G->A / 376A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Murcia Oristano	Not Available	209A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Ube Konan	Not Available	241C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Lagosanto	Not Available	242G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Guangzhou	Not Available	274C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Hammersmith	Not Available	323T->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Sinnai	Not Available	34G->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	A- (680)	Not Available	376A->G / 680G->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	A- (968), Betica,Selma, Guantanamo	Not Available	376A->G / 968T->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Salerno Pyrgos	Not Available	383T>G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Quing Yan	Not Available	392G->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Lages	Not Available	40G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Ilesha	Not Available	466G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Mahidol	Not Available	487G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Malaga	Not Available	542A->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Sibari	Not Available	634A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Mexico City	Not Available	680G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Nanning	Not Available	703C->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Seattle, Lodi, Modena, Ferrara II, Athens-like	Not Available	844G->C	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Bajo Maumere	Not Available	844G->T	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Montalbano	Not Available	854G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Kalyan-Kerala, Jamnaga, Rohini	Not Available	949G->A	ADR Inferred	Increased risk of hemolytic anemia.	Details
Glucose-6-phosphate 1-dehydrogenase	Gaohe	Not Available	95A->G	ADR Inferred	Increased risk of hemolytic anemia.	Details

Interactions

Drug Interactions

Drug	Interaction	Drug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE	7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Glimepiride.	Experimental
Abiraterone	The metabolism of Glimepiride can be decreased when combined with Abiraterone.	Approved
Acarbose	Acarbose may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Acebutolol	Acebutolol may increase the hypoglycemic activities of Glimepiride.	Approved
Acenocoumarol	Glimepiride may increase the anticoagulant activities of Acenocoumarol.	Approved
Acetohexamide	Acetohexamide may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Acetylsalicylic acid	Acetylsalicylic acid may increase the hypoglycemic activities of Glimepiride.	Approved, Vet Approved
AICA ribonucleotide	Aicar may increase the hypoglycemic activities of Glimepiride.	Experimental
Albiglutide	Albiglutide may increase the hypoglycemic activities of Glimepiride.	Approved
Alogliptin	Alogliptin may increase the hypoglycemic activities of Glimepiride.	Approved
Alprenolol	Alprenolol may increase the hypoglycemic activities of Glimepiride.	Approved, Withdrawn
Aminosalicylic Acid	Aminosalicylic Acid may increase the hypoglycemic activities of Glimepiride.	Approved
Amiodarone	The metabolism of Glimepiride can be decreased when combined with Amiodarone.	Approved, Investigational
Aprepitant	The metabolism of Glimepiride can be increased when combined with Aprepitant.	Approved, Investigational
Aripiprazole	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Aripiprazole.	Approved, Investigational
Arotinolol	Arotinolol may increase the hypoglycemic activities of Glimepiride.	Approved
Arsenic trioxide	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Arsenic trioxide.	Approved, Investigational
Articaine	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Articaine.	Approved
Asenapine	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Asenapine.	Approved
Atazanavir	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Atazanavir.	Approved, Investigational
Atenolol	Atenolol may increase the hypoglycemic activities of Glimepiride.	Approved
Atorvastatin	Atorvastatin may increase the hypoglycemic activities of Glimepiride.	Approved
Balsalazide	Balsalazide may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Befunolol	Befunolol may increase the hypoglycemic activities of Glimepiride.	Experimental
Bendroflumethiazide	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Bendroflumethiazide.	Approved
Benmoxin	Benmoxin may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Betamethasone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Betamethasone.	Approved, Vet Approved
Betaxolol	Betaxolol may increase the hypoglycemic activities of Glimepiride.	Approved
Bevantolol	Bevantolol may increase the hypoglycemic activities of Glimepiride.	Approved
Bezafibrate	Bezafibrate may increase the hypoglycemic activities of Glimepiride.	Approved
Bisoprolol	Bisoprolol may increase the hypoglycemic activities of Glimepiride.	Approved
Bopindolol	Bopindolol may increase the hypoglycemic activities of Glimepiride.	Approved
Brexpiprazole	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Brexpiprazole.	Approved
Buformin	Buformin may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Bufuralol	Bufuralol may increase the hypoglycemic activities of Glimepiride.	Experimental, Investigational
Bumetanide	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Bumetanide.	Approved
Bupranolol	Bupranolol may increase the hypoglycemic activities of Glimepiride.	Approved
Buserelin	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Buserelin.	Approved
Canagliflozin	Canagliflozin may increase the hypoglycemic activities of Glimepiride.	Approved
Capecitabine	The metabolism of Glimepiride can be decreased when combined with Capecitabine.	Approved, Investigational
Carbamazepine	The metabolism of Glimepiride can be increased when combined with Carbamazepine.	Approved, Investigational
Carbocisteine	The risk or severity of adverse effects can be increased when Glimepiride is combined with Carbocisteine.	Approved
Caroxazone	Caroxazone may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Carteolol	Carteolol may increase the hypoglycemic activities of Glimepiride.	Approved
Carvedilol	Carvedilol may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Castanospermine	Castanospermine may increase the hypoglycemic activities of Glimepiride.	Experimental
Celiprolol	Celiprolol may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Ceritinib	The serum concentration of Glimepiride can be increased when it is combined with Ceritinib.	Approved
Chloramphenicol	The metabolism of Glimepiride can be decreased when combined with Chloramphenicol.	Approved, Vet Approved
Chlorothiazide	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorothiazide.	Approved, Vet Approved
Chlorpropamide	Glimepiride may increase the hypoglycemic activities of Chlorpropamide.	Approved
Chlorthalidone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorthalidone.	Approved
Cholecalciferol	The metabolism of Glimepiride can be decreased when combined with Cholecalciferol.	Approved, Nutraceutical
Ciglitazone	Ciglitazone may increase the hypoglycemic activities of Glimepiride.	Experimental
Cimetidine	The serum concentration of Glimepiride can be increased when it is combined with Cimetidine.	Approved
Cinoxacin	Cinoxacin may increase the hypoglycemic activities of Glimepiride.	Approved, Withdrawn
Ciprofloxacin	Ciprofloxacin may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Citalopram	Citalopram may increase the hypoglycemic activities of Glimepiride.	Approved
Clofibrate	Clofibrate may increase the hypoglycemic activities of Glimepiride.	Approved
Clotrimazole	The metabolism of Glimepiride can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Clozapine.	Approved
Colesevelam	The serum concentration of Glimepiride can be decreased when it is combined with Colesevelam.	Approved
Corticotropin	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Corticotropin.	Approved, Vet Approved
Cortisone acetate	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Cortisone acetate.	Approved
Cyclosporine	The metabolism of Glimepiride can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyproterone acetate	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Cyproterone acetate.	Approved, Investigational
Dabrafenib	The serum concentration of Glimepiride can be decreased when it is combined with Dabrafenib.	Approved
Danazol	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Danazol.	Approved
Dapoxetine	Dapoxetine may increase the hypoglycemic activities of Glimepiride.	Investigational
Darunavir	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Darunavir.	Approved
Delavirdine	The metabolism of Glimepiride can be decreased when combined with Delavirdine.	Approved
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Glimepiride.	Approved
Desogestrel	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Desogestrel.	Approved
Desvenlafaxine	Desvenlafaxine may increase the hypoglycemic activities of Glimepiride.	Approved
Dexamethasone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Dexamethasone.	Approved, Investigational, Vet Approved
Diazoxide	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Diazoxide.	Approved
Dicoumarol	Glimepiride may increase the anticoagulant activities of Dicoumarol.	Approved
Dienogest	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Dienogest.	Approved
Diflunisal	Diflunisal may increase the hypoglycemic activities of Glimepiride.	Approved
Dihydrotestosterone	Dihydrotestosterone may increase the hypoglycemic activities of Glimepiride.	Illicit
Disopyramide	Glimepiride may increase the hypoglycemic activities of Disopyramide.	Approved
Drospirenone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Drospirenone.	Approved
Dulaglutide	Dulaglutide may increase the hypoglycemic activities of Glimepiride.	Approved
Duloxetine	Duloxetine may increase the hypoglycemic activities of Glimepiride.	Approved
Efavirenz	The metabolism of Glimepiride can be decreased when combined with Efavirenz.	Approved, Investigational
Empagliflozin	Empagliflozin may increase the hypoglycemic activities of Glimepiride.	Approved
Enoxacin	Enoxacin may increase the hypoglycemic activities of Glimepiride.	Approved
Epinephrine	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Epinephrine.	Approved, Vet Approved
Escitalopram	Escitalopram may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Esmolol	Esmolol may increase the hypoglycemic activities of Glimepiride.	Approved
Estradiol	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Estradiol.	Approved, Investigational, Vet Approved
Estrone sulfate	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Estrone sulfate.	Approved
Etacrynic acid	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Etacrynic acid.	Approved
Ethanol	The risk or severity of adverse effects can be increased when Glimepiride is combined with Ethanol.	Approved
Ethinyl Estradiol	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ethinyl Estradiol.	Approved
Ethyl biscoumacetate	Glimepiride may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Ethynodiol diacetate	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ethynodiol diacetate.	Approved
Etofibrate	Etofibrate may increase the hypoglycemic activities of Glimepiride.	Approved
Etonogestrel	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Etonogestrel.	Approved, Investigational
Etoperidone	Etoperidone may increase the hypoglycemic activities of Glimepiride.	Approved
Etravirine	The metabolism of Glimepiride can be decreased when combined with Etravirine.	Approved
Everolimus	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Everolimus.	Approved
Exenatide	Exenatide may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Fenofibrate	Fenofibrate may increase the hypoglycemic activities of Glimepiride.	Approved
Fingolimod	Glimepiride may increase the immunosuppressive activities of Fingolimod.	Approved, Investigational
Fleroxacin	Fleroxacin may increase the hypoglycemic activities of Glimepiride.	Approved
Floxuridine	The metabolism of Glimepiride can be decreased when combined with Floxuridine.	Approved
Fluconazole	The serum concentration of Glimepiride can be increased when it is combined with Fluconazole.	Approved
Fludrocortisone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Fludrocortisone.	Approved
Flumequine	Flumequine may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Fluorouracil	The metabolism of Glimepiride can be decreased when combined with Fluorouracil.	Approved
Fluoxetine	Fluoxetine may increase the hypoglycemic activities of Glimepiride.	Approved, Vet Approved
Fluoxymesterone	Fluoxymesterone may increase the hypoglycemic activities of Glimepiride.	Approved, Illicit
Fluvastatin	The metabolism of Glimepiride can be decreased when combined with Fluvastatin.	Approved
Fluvoxamine	The metabolism of Glimepiride can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Fosamprenavir.	Approved
Fosphenytoin	The metabolism of Glimepiride can be increased when combined with Fosphenytoin.	Approved
Furazolidone	Furazolidone may increase the hypoglycemic activities of Glimepiride.	Approved, Vet Approved
Furosemide	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Furosemide.	Approved, Vet Approved
G17DT	The risk or severity of adverse effects can be increased when Glimepiride is combined with G17DT.	Investigational
Gatifloxacin	Gatifloxacin may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Gemfibrozil	The metabolism of Glimepiride can be decreased when combined with Gemfibrozil.	Approved
Gemifloxacin	Gemifloxacin may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Glibornuride	Glibornuride may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Gliclazide	Glimepiride may increase the hypoglycemic activities of Gliclazide.	Approved
Glipizide	Glimepiride may increase the hypoglycemic activities of Glipizide.	Approved
Gliquidone	Gliquidone may increase the hypoglycemic activities of Glimepiride.	Approved
Glyburide	Glimepiride may increase the hypoglycemic activities of Glyburide.	Approved
Goserelin	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Goserelin.	Approved
Grepafloxacin	Grepafloxacin may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Histrelin	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Histrelin.	Approved
Hydracarbazine	Hydracarbazine may increase the hypoglycemic activities of Glimepiride.	Approved
Hydrochlorothiazide	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrochlorothiazide.	Approved, Vet Approved
Hydrocortisone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrocortisone.	Approved, Vet Approved
Hydroflumethiazide	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydroflumethiazide.	Approved
Hydroxyprogesterone caproate	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydroxyprogesterone caproate.	Approved
Iloperidone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Iloperidone.	Approved
Indalpine	Indalpine may increase the hypoglycemic activities of Glimepiride.	Investigational, Withdrawn
Indapamide	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Indapamide.	Approved
Indenolol	Indenolol may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Indinavir	The metabolism of Glimepiride can be decreased when combined with Indinavir.	Approved
INGN 201	The risk or severity of adverse effects can be increased when Glimepiride is combined with INGN 201.	Investigational
INGN 225	The risk or severity of adverse effects can be increased when Glimepiride is combined with INGN 225.	Investigational
Insulin Aspart	Glimepiride may increase the hypoglycemic activities of Insulin Aspart.	Approved
Insulin Detemir	Glimepiride may increase the hypoglycemic activities of Insulin Detemir.	Approved
Insulin Glargine	Insulin Glargine may increase the hypoglycemic activities of Glimepiride.	Approved
Insulin Glulisine	Glimepiride may increase the hypoglycemic activities of Insulin Glulisine.	Approved
Insulin Human	Insulin Human may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Insulin Lispro	Insulin Lispro may increase the hypoglycemic activities of Glimepiride.	Approved
Insulin Pork	Insulin Pork may increase the hypoglycemic activities of Glimepiride.	Approved
Iproclozide	Iproclozide may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Iproniazid	Iproniazid may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Irbesartan	The metabolism of Glimepiride can be decreased when combined with Irbesartan.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the hypoglycemic activities of Glimepiride.	Approved
Ketoconazole	The metabolism of Glimepiride can be decreased when combined with Ketoconazole.	Approved, Investigational
Labetalol	Labetalol may increase the hypoglycemic activities of Glimepiride.	Approved
Lanreotide	Glimepiride may increase the hypoglycemic activities of Lanreotide.	Approved
Leflunomide	The risk or severity of adverse effects can be increased when Glimepiride is combined with Leflunomide.	Approved, Investigational
Leuprolide	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Leuprolide.	Approved, Investigational
Levobunolol	Levobunolol may increase the hypoglycemic activities of Glimepiride.	Approved
Levofloxacin	Levofloxacin may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Levomilnacipran	Levomilnacipran may increase the hypoglycemic activities of Glimepiride.	Approved
Levonorgestrel	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Levonorgestrel.	Approved, Investigational
Linagliptin	Linagliptin may increase the hypoglycemic activities of Glimepiride.	Approved
Lipoic Acid	Lipoic Acid may increase the hypoglycemic activities of Glimepiride.	Approved, Nutraceutical
Liraglutide	Liraglutide may increase the hypoglycemic activities of Glimepiride.	Approved
Lomefloxacin	Lomefloxacin may increase the hypoglycemic activities of Glimepiride.	Approved
Lopinavir	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Lopinavir.	Approved
Losartan	The metabolism of Glimepiride can be decreased when combined with Losartan.	Approved
Lovastatin	The metabolism of Glimepiride can be decreased when combined with Lovastatin.	Approved, Investigational
Lumacaftor	The serum concentration of Glimepiride can be decreased when it is combined with Lumacaftor.	Approved
Lurasidone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Lurasidone.	Approved
Mebanazine	Mebanazine may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Mecasermin	Glimepiride may increase the hypoglycemic activities of Mecasermin.	Approved, Investigational
Medroxyprogesterone acetate	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Medroxyprogesterone acetate.	Approved, Investigational
Megestrol acetate	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Megestrol acetate.	Approved, Vet Approved
Mesalazine	Mesalazine may increase the hypoglycemic activities of Glimepiride.	Approved
Mestranol	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Mestranol.	Approved
Metformin	Metformin may increase the hypoglycemic activities of Glimepiride.	Approved
Methotrimeprazine	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Methotrimeprazine.	Approved
Methyclothiazide	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Methyclothiazide.	Approved
Methylene blue	Methylene blue may increase the hypoglycemic activities of Glimepiride.	Investigational
Methylprednisolone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Methylprednisolone.	Approved, Vet Approved
Methyltestosterone	Methyltestosterone may increase the hypoglycemic activities of Glimepiride.	Approved
Metipranolol	Metipranolol may increase the hypoglycemic activities of Glimepiride.	Approved
Metolazone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Metolazone.	Approved
Metoprolol	Metoprolol may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Metreleptin	Metreleptin may increase the hypoglycemic activities of Glimepiride.	Approved
Miconazole	Miconazole may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational, Vet Approved
Mifepristone	The serum concentration of Glimepiride can be increased when it is combined with Mifepristone.	Approved, Investigational
Miglitol	Miglitol may increase the hypoglycemic activities of Glimepiride.	Approved
Miglustat	Miglustat may increase the hypoglycemic activities of Glimepiride.	Approved
Milnacipran	Milnacipran may increase the hypoglycemic activities of Glimepiride.	Approved
Minaprine	Minaprine may increase the hypoglycemic activities of Glimepiride.	Approved
Mitiglinide	Mitiglinide may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Moclobemide	Moclobemide may increase the hypoglycemic activities of Glimepiride.	Approved
Moxifloxacin	Moxifloxacin may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Nadolol	Nadolol may increase the hypoglycemic activities of Glimepiride.	Approved
Nalidixic Acid	Nalidixic Acid may increase the hypoglycemic activities of Glimepiride.	Approved
Natalizumab	The risk or severity of adverse effects can be increased when Glimepiride is combined with Natalizumab.	Approved, Investigational
Nateglinide	Glimepiride may increase the hypoglycemic activities of Nateglinide.	Approved, Investigational
NCX 4016	NCX 4016 may increase the hypoglycemic activities of Glimepiride.	Investigational
Nefazodone	Nefazodone may increase the hypoglycemic activities of Glimepiride.	Approved, Withdrawn
Nelfinavir	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Nelfinavir.	Approved
Niacin	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Niacin.	Approved, Investigational, Nutraceutical
Nialamide	Nialamide may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Nicardipine	The metabolism of Glimepiride can be decreased when combined with Nicardipine.	Approved
Nilotinib	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Nilotinib.	Approved, Investigational
Norethisterone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Norethisterone.	Approved
Norfloxacin	Norfloxacin may increase the hypoglycemic activities of Glimepiride.	Approved
Norgestimate	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Norgestimate.	Approved
Octamoxin	Octamoxin may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Octreotide	Octreotide may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Ofloxacin	Ofloxacin may increase the hypoglycemic activities of Glimepiride.	Approved
Olanzapine	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Olanzapine.	Approved, Investigational
Olsalazine	Olsalazine may increase the hypoglycemic activities of Glimepiride.	Approved
Omeprazole	The metabolism of Glimepiride can be decreased when combined with Omeprazole.	Approved, Investigational, Vet Approved
Oxandrolone	Oxandrolone may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Oxprenolol	Oxprenolol may increase the hypoglycemic activities of Glimepiride.	Approved
Oxymetholone	Oxymetholone may increase the hypoglycemic activities of Glimepiride.	Approved, Illicit
Paliperidone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Paliperidone.	Approved
Pargyline	Pargyline may increase the hypoglycemic activities of Glimepiride.	Approved
Paroxetine	Paroxetine may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Pasireotide	Glimepiride may increase the hypoglycemic activities of Pasireotide.	Approved
Pefloxacin	Pefloxacin may increase the hypoglycemic activities of Glimepiride.	Approved
Pegvisomant	Pegvisomant may increase the hypoglycemic activities of Glimepiride.	Approved
Penbutolol	Penbutolol may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Pentamidine	Glimepiride may increase the hypoglycemic activities of Pentamidine.	Approved
Phenelzine	Phenelzine may increase the hypoglycemic activities of Glimepiride.	Approved
Phenformin	Phenformin may increase the hypoglycemic activities of Glimepiride.	Approved, Withdrawn
Phenindione	Glimepiride may increase the anticoagulant activities of Phenindione.	Approved
Pheniprazine	Pheniprazine may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Phenobarbital	The metabolism of Glimepiride can be increased when combined with Phenobarbital.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Phenprocoumon	Glimepiride may increase the anticoagulant activities of Phenprocoumon.	Approved
Phenytoin	The metabolism of Glimepiride can be increased when combined with Phenytoin.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Glimepiride.	Approved, Investigational
Pindolol	Pindolol may increase the hypoglycemic activities of Glimepiride.	Approved
Pioglitazone	Pioglitazone may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Piperazine	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Piperazine.	Approved, Vet Approved
Pipotiazine	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Pipotiazine.	Approved
Pirlindole	Pirlindole may increase the hypoglycemic activities of Glimepiride.	Approved
Pivhydrazine	Pivhydrazine may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Polythiazide	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Polythiazide.	Approved
Practolol	Practolol may increase the hypoglycemic activities of Glimepiride.	Approved
Pramlintide	Pramlintide may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Prednisolone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Prednisolone.	Approved, Vet Approved
Prednisone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Prednisone.	Approved, Vet Approved
Primidone	The metabolism of Glimepiride can be increased when combined with Primidone.	Approved, Vet Approved
Probenecid	The protein binding of Glimepiride can be decreased when combined with Probenecid.	Approved
Progesterone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Progesterone.	Approved, Vet Approved
Propranolol	Propranolol may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Pyrimethamine	The metabolism of Glimepiride can be decreased when combined with Pyrimethamine.	Approved, Vet Approved
Quetiapine	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Quetiapine.	Approved
Quinethazone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Quinethazone.	Approved
Quinine	Glimepiride may increase the hypoglycemic activities of Quinine.	Approved
Ranitidine	The serum concentration of Glimepiride can be increased when it is combined with Ranitidine.	Approved
Rasagiline	Rasagiline may increase the hypoglycemic activities of Glimepiride.	Approved
Repaglinide	Glimepiride may increase the hypoglycemic activities of Repaglinide.	Approved, Investigational
Rifampicin	The serum concentration of Glimepiride can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The metabolism of Glimepiride can be increased when combined with Rifapentine.	Approved
Rindopepimut	The risk or severity of adverse effects can be increased when Glimepiride is combined with CDX-110.	Investigational
Risperidone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Risperidone.	Approved, Investigational
Ritonavir	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ritonavir.	Approved, Investigational
Roflumilast	Roflumilast may increase the immunosuppressive activities of Glimepiride.	Approved
Rosiglitazone	Rosiglitazone may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Rosoxacin	Rosoxacin may increase the hypoglycemic activities of Glimepiride.	Approved
Safrazine	Safrazine may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Salicylic acid	Salicylic acid may increase the hypoglycemic activities of Glimepiride.	Approved, Vet Approved
Saquinavir	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Saquinavir.	Approved, Investigational
Saxagliptin	Saxagliptin may increase the hypoglycemic activities of Glimepiride.	Approved
Secobarbital	The metabolism of Glimepiride can be increased when combined with Secobarbital.	Approved, Vet Approved
Selegiline	Selegiline may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational, Vet Approved
Sertraline	Sertraline may increase the hypoglycemic activities of Glimepiride.	Approved
Sildenafil	The metabolism of Glimepiride can be decreased when combined with Sildenafil.	Approved, Investigational
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Glimepiride.	Approved
Sirolimus	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Sirolimus.	Approved, Investigational
Sitagliptin	Sitagliptin may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Sorafenib	The metabolism of Glimepiride can be decreased when combined with Sorafenib.	Approved, Investigational
Sotalol	Sotalol may increase the hypoglycemic activities of Glimepiride.	Approved
Sparfloxacin	Sparfloxacin may increase the hypoglycemic activities of Glimepiride.	Approved
SRP 299	The risk or severity of adverse effects can be increased when Glimepiride is combined with SRP 299.	Investigational
Stanozolol	Stanozolol may increase the hypoglycemic activities of Glimepiride.	Approved, Vet Approved
Sulfadiazine	The metabolism of Glimepiride can be decreased when combined with Sulfadiazine.	Approved, Vet Approved
Sulfamethoxazole	Glimepiride may increase the hypoglycemic activities of Sulfamethoxazole.	Approved
Sulfisoxazole	The metabolism of Glimepiride can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulodexide	Sulodexide may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Sunitinib	Glimepiride may increase the hypoglycemic activities of Sunitinib.	Approved, Investigational
Tacrolimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Glimepiride.	Approved, Investigational
Tacrolimus	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Tacrolimus.	Approved, Investigational
Temafloxacin	Temafloxacin may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Temsirolimus	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Temsirolimus.	Approved
Testosterone	Testosterone may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Ticagrelor	The metabolism of Glimepiride can be decreased when combined with Ticagrelor.	Approved
Ticlopidine	The metabolism of Glimepiride can be decreased when combined with Ticlopidine.	Approved
Timolol	Timolol may increase the hypoglycemic activities of Glimepiride.	Approved
Tipranavir	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Tipranavir.	Approved, Investigational
Tofacitinib	Glimepiride may increase the immunosuppressive activities of Tofacitinib.	Approved, Investigational
Tolazamide	Glimepiride may increase the hypoglycemic activities of Tolazamide.	Approved
Tolbutamide	The metabolism of Glimepiride can be decreased when combined with Tolbutamide.	Approved
Toloxatone	Toloxatone may increase the hypoglycemic activities of Glimepiride.	Approved
Torasemide	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Torasemide.	Approved
Trans-2-Phenylcyclopropylamine	Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Glimepiride.	Experimental
Tranylcypromine	Tranylcypromine may increase the hypoglycemic activities of Glimepiride.	Approved
Trastuzumab	Trastuzumab may increase the neutropenic activities of Glimepiride.	Approved, Investigational
Triamcinolone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Triamcinolone.	Approved, Vet Approved
Trichlormethiazide	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Trichlormethiazide.	Approved, Vet Approved
Trimethoprim	The metabolism of Glimepiride can be decreased when combined with Trimethoprim.	Approved, Vet Approved
Triptorelin	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Triptorelin.	Approved, Vet Approved
Troglitazone	Troglitazone may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Trovafloxacin	Trovafloxacin may increase the hypoglycemic activities of Glimepiride.	Approved, Withdrawn
Valproic Acid	The metabolism of Glimepiride can be decreased when combined with Valproic Acid.	Approved, Investigational
Valsartan	The metabolism of Glimepiride can be decreased when combined with Valsartan.	Approved, Investigational
Venlafaxine	Venlafaxine may increase the hypoglycemic activities of Glimepiride.	Approved
Vildagliptin	Vildagliptin may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Voglibose	Voglibose may increase the hypoglycemic activities of Glimepiride.	Approved, Investigational
Voriconazole	The serum concentration of Glimepiride can be increased when it is combined with Voriconazole.	Approved, Investigational
Vorinostat	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Vorinostat.	Approved, Investigational
Warfarin	Glimepiride may increase the anticoagulant activities of Warfarin.	Approved
Zafirlukast	The metabolism of Glimepiride can be decreased when combined with Zafirlukast.	Approved, Investigational
Zimelidine	Zimelidine may increase the hypoglycemic activities of Glimepiride.	Withdrawn
Ziprasidone	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ziprasidone.	Approved

Food Interactions

Avoid alcohol.
Even though food reduces product absorption, the manufacturer recommends taking the product with the first meal of the day.

References

Synthesis Reference

Suresh Kadam, Venkatasubramanian Tarur, Sanjay Naik, Sachin Gavhane, "Process for preparation of substantially pure glimepiride." U.S. Patent US20070082943, issued April 12, 2007.

US20070082943

General References

Not Available

External Links

Resource	Link
KEGG Drug	D00593
KEGG Compound	C07669
ChemSpider	16740595
ChEBI	5383
ChEMBL	CHEMBL1481
Therapeutic Targets Database	DAP000132
PharmGKB	PA449761
Drug Product Database	12597
RxList	http://www.rxlist.com/cgi/generic/glimepiride.htm
Drugs.com	http://www.drugs.com/cdi/glimepiride.html
Wikipedia	Glimepiride

ATC Codes

A10BD06

A10BD04

A10BB12

AHFS Codes

68:20.20

PDB Entries

Not Available

FDA label

Download (176 KB)

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers	3
1	Completed	Not Available	Pharmacokinetics	1
1	Completed	Not Available	Type 2 Diabetes Mellitus	1
1	Completed	Basic Science	Healthy Volunteers	2
1	Completed	Treatment	Diabetes / Type 2 Diabetes Mellitus	1
1	Completed	Treatment	Healthy Volunteers	5
1	Completed	Treatment	Type 2 Diabetes Mellitus	3
1	Completed	Treatment	Type2 Diabetes Mellitus	1
1	Not Yet Recruiting	Health Services Research	Type2 Diabetes	1
1	Not Yet Recruiting	Treatment	Diabetes Mellitus (DM)	1
1	Terminated	Treatment	Type 2 Diabetes Mellitus	1
2	Completed	Not Available	Diabetes / Type 2 Diabetes Mellitus	1
2	Completed	Treatment	Congestive Heart Failure (CHF) / Type 2 Diabetes Mellitus	1
2	Completed	Treatment	Diabetes / Type 2 Diabetes Mellitus	1
2	Completed	Treatment	Impaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus	1
2	Completed	Treatment	Type 2 Diabetes Mellitus	5
2	Withdrawn	Treatment	Type 2 Diabetes Mellitus	1
2, 3	Completed	Treatment	Maturity-Onset Diabetes of the Young	1
2, 3	Completed	Treatment	Type 2 Diabetes Mellitus	2
3	Active Not Recruiting	Treatment	Diabetes	1
3	Active Not Recruiting	Treatment	Type 2 Diabetes Mellitus	3
3	Completed	Prevention	Atherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus	1
3	Completed	Treatment	Diabetes Mellitus (DM)	3
3	Completed	Treatment	Diabetes Mellitus (DM) / Dyslipidemias	1
3	Completed	Treatment	Diabetes Mellitus, Non-Insulin-Dependent	1
3	Completed	Treatment	Diabetes Mellitus, Non-Insulin-Dependent / Type 2 Diabetes Mellitus, Non Insulin Dependent	1
3	Completed	Treatment	Diabetes / Type 2 Diabetes Mellitus	5
3	Completed	Treatment	Diabetics Patients	1
3	Completed	Treatment	Type 2 Diabetes Mellitus	43
3	Not Yet Recruiting	Health Services Research	Diabetes Mellitus (DM)	1
3	Not Yet Recruiting	Treatment	Type 2 Diabetes Mellitus	1
3	Recruiting	Treatment	Comparative Effectiveness of Glycemia-lowering Medications / Type 2 Diabetes Mellitus	1
3	Recruiting	Treatment	Type 2 Diabetes Mellitus	2
3	Terminated	Treatment	Diabetes / Type 2 Diabetes Mellitus	4
3	Terminated	Treatment	Type 2 Diabetes Mellitus	7
3	Withdrawn	Treatment	Type 2 Diabetes Mellitus	2
4	Active Not Recruiting	Treatment	Type 2 Diabetes Mellitus	3
4	Completed	Treatment	Diabetes	1
4	Completed	Treatment	Diabetes Mellitus (DM)	2
4	Completed	Treatment	Diabetes Mellitus (DM) / Endothelial Dysfunction	1
4	Completed	Treatment	Diabetes Mellitus, Non-Insulin-Dependent	1
4	Completed	Treatment	Diabetes / Type 2 Diabetes Mellitus	3
4	Completed	Treatment	Glucotoxicity / Pancreatic Beta Cell Function / Type 2 Diabetes Mellitus	1
4	Completed	Treatment	Hypoglycemia / Type 2 Diabetes Mellitus	1
4	Completed	Treatment	Inadequate Glycaemic Control / Type 2 Diabetes Mellitus / Type2 Diabetes Mellitus	1
4	Completed	Treatment	Insulin Resistance / Type 2 Diabetes Mellitus	1
4	Completed	Treatment	Type 2 Diabetes Mellitus	22
4	Enrolling by Invitation	Treatment	Microalbuminuria / Microalbuminuria /Creatinine Ratios ACR	1
4	Not Yet Recruiting	Treatment	Type 2 Diabetes Mellitus	1
4	Recruiting	Treatment	Cardiovascular Disease (CVD) / Type2 Diabetes	1
4	Recruiting	Treatment	Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications	1
4	Recruiting	Treatment	Non-Alcoholic Fatty Liver Disease (NAFLD)	1
4	Recruiting	Treatment	Type 2 Diabetes Mellitus	8
4	Terminated	Treatment	Type 2 Diabetes Mellitus	4
4	Unknown Status	Not Available	Type 2 Diabetes Mellitus	1
4	Unknown Status	Basic Science	Type 2 Diabetes Mellitus	1
4	Unknown Status	Treatment	Type 2 Diabetes Mellitus	3
4	Withdrawn	Not Available	Type 2 Diabetes Mellitus	1
Not Available	Completed	Not Available	Healthy Volunteers	2
Not Available	Completed	Not Available	Type 2 Diabetes Mellitus	6
Not Available	Completed	Treatment	Atherosclerosis / Impaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus	1
Not Available	Completed	Treatment	Pre-Diabetic / Type 2 Diabetes Mellitus	1
Not Available	Completed	Treatment	Type 2 Diabetes Mellitus	4
Not Available	Not Yet Recruiting	Not Available	Type 2 Diabetes Mellitus	1
Not Available	Not Yet Recruiting	Treatment	Type 2 Diabetes Mellitus	1
Not Available	Recruiting	Not Available	Cardiovascular Disease (CVD) / Type 2 Diabetes Mellitus	1
Not Available	Recruiting	Basic Science	Maturity-Onset Diabetes of the Young, Type 3	1
Not Available	Recruiting	Prevention	Coronary Heart Disease (CHD)	1
Not Available	Recruiting	Treatment	Diabetes	1
Not Available	Recruiting	Treatment	Type2 Diabetes Mellitus	1
Not Available	Unknown Status	Not Available	Type 2 Diabetes Mellitus	1

Pharmacoeconomics

Manufacturers

Sanofi aventis us llc
Accord healthcare inc
Carlsbad technology inc
Corepharma llc
Dr reddys laboratories ltd
Genpharm inc
Invagen pharmaceuticals inc
Mylan pharmaceuticals inc
Ranbaxy laboratories ltd
Teva pharmaceuticals usa inc
Vintage pharmaceuticals llc
Watson laboratories inc
Watson laboratories inc florida

Packagers

Accord Healthcare
Advanced Pharmaceutical Services Inc.
Amerisource Health Services Corp.
A-S Medication Solutions LLC
Bryant Ranch Prepack
Cardinal Health
Carlsbad Technology Inc.
Cobalt Pharmaceuticals Inc.
Corepharma LLC
Dispensing Solutions
Diversified Healthcare Services Inc.
Doctor Reddys Laboratories Ltd.
Heartland Repack Services LLC
Intas Pharmaceuticals Ltd.
International Laboratories Inc.
InvaGen Pharmaceuticals Inc.
Ivax Pharmaceuticals
Lake Erie Medical and Surgical Supply
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Nucare Pharmaceuticals Inc.
PD-Rx Pharmaceuticals Inc.
Perrigo Co.
Pharmacy Service Center
Physicians Total Care Inc.
Prasco Labs
Prepak Systems Inc.
Ranbaxy Laboratories
Rebel Distributors Corp.
Resource Optimization and Innovation LLC
Sandoz
Sanofi-Aventis Inc.
Southwood Pharmaceuticals
Stat Scripts LLC
Teva Pharmaceutical Industries Ltd.
UDL Laboratories
Vangard Labs Inc.

Dosage forms

Form	Route	Strength
Tablet	Oral	1 mg
Tablet	Oral	2 mg
Tablet	Oral	4 mg
Tablet	Oral
Tablet, film coated	Oral
Tablet	Oral	1 mg/1
Tablet	Oral	2 mg/1
Tablet	Oral	3 mg/1
Tablet	Oral	4 mg/1
Tablet	Oral	6 mg/1
Tablet	Oral	8 mg/1
Tablet	Oral	3 mg

Prices

Unit description	Cost	Unit
Amaryl 4 mg tablet	2.11USD	tablet
Amaryl 2 mg tablet	1.25USD	tablet
Glimepiride 4 mg tablet	1.25USD	tablet
Amaryl 1 mg tablet	0.88USD	tablet
Glimepiride 2 mg tablet	0.67USD	tablet
Glimepiride 1 mg tablet	0.42USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US6150383	No	1996-06-19	2016-06-19	US
US6211205	No	1996-06-19	2016-06-19	US
US6303640	No	1996-08-09	2016-08-09	US
US6329404	No	1996-06-19	2016-06-19	US
US7358366	Yes	2000-10-19	2020-10-19	US
US7538125	No	1996-06-19	2016-06-19	US
US7700128	No	2007-01-30	2027-01-30	US
US8071130	No	2008-06-08	2028-06-08	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	207 °C	Not Available
water solubility	Insoluble	Not Available
logP	3.5	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0347 mg/mL	ALOGPS
logP	3.03	ALOGPS
logP	4.76	ChemAxon
logS	-4.2	ALOGPS
pKa (Strongest Acidic)	2.23	ChemAxon
pKa (Strongest Basic)	-0.36	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	7	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	131.66 Å²	ChemAxon
Rotatable Bond Count	6	ChemAxon
Refractivity	130.85 m³·mol^-1	ChemAxon
Polarizability	53.31 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.986
Blood Brain Barrier	+	0.7322
Caco-2 permeable	-	0.6809
P-glycoprotein substrate	Substrate	0.7501
P-glycoprotein inhibitor I	Non-inhibitor	0.6556
P-glycoprotein inhibitor II	Inhibitor	0.6124
Renal organic cation transporter	Non-inhibitor	0.8241
CYP450 2C9 substrate	Substrate	0.5661
CYP450 2D6 substrate	Non-substrate	0.9116
CYP450 3A4 substrate	Non-substrate	0.5978
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Inhibitor	0.8949
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Non-inhibitor	0.8309
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8599
Ames test	Non AMES toxic	0.6392
Carcinogenicity	Non-carcinogens	0.7301
Biodegradation	Not ready biodegradable	0.68
Rat acute toxicity	2.4158 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.7714
hERG inhibition (predictor II)	Non-inhibitor	0.8263

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-03di-0012290000-966a50af984de12b0ba8	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-0udi-2629000000-29b987358cc85159c5b8	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-03di-0002190000-0aaefa2e07605da97f81	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-0udi-0409000000-91b493608ac508427593	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-004i-3911000000-78c0f40c965f78bfa591	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Benzenesulfonamides

Direct Parent

Benzenesulfonamides

Alternative Parents

Benzenesulfonyl compounds / Pyrroline carboxylic acids and derivatives / Ureides / Sulfonylureas / Organosulfonic acids and derivatives / Dicarboximides / Aminosulfonyl compounds / Azacyclic compounds / Organic oxides / Hydrocarbon derivatives

Substituents

Benzenesulfonamide / Benzenesulfonyl group / Pyrroline carboxylic acid or derivatives / Ureide / Sulfonylurea / Dicarboximide / Pyrroline / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Aminosulfonyl compound

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

sulfonamide, N-sulfonylurea, N-acylurea (CHEBI:5383 )

Targets

Details

1. ATP-sensitive inward rectifier potassium channel 11

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Voltage-gated potassium channel activity
Specific Function:: This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectific...
Gene Name:: KCNJ11
Uniprot ID:: Q14654
Molecular Weight:: 43540.375 Da

References

Song DK, Ashcroft FM: Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol. 2001 May;133(1):193-9. [PubMed:11325810 ]
Lawrence CL, Rainbow RD, Davies NW, Standen NB: Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels. Br J Pharmacol. 2002 Jul;136(5):746-52. [PubMed:12086984 ]
Bataille D: [Molecular mechanisms of insulin secretion]. Diabetes Metab. 2002 Dec;28(6 Suppl):4S7-13. [PubMed:12703060 ]

Details

2. ATP-sensitive inward rectifier potassium channel 1

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Phosphatidylinositol-4,5-bisphosphate binding
Specific Function:: In the kidney, probably plays a major role in potassium homeostasis. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive vol...
Gene Name:: KCNJ1
Uniprot ID:: P48048
Molecular Weight:: 44794.6 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Proks P, Reimann F, Green N, Gribble F, Ashcroft F: Sulfonylurea stimulation of insulin secretion. Diabetes. 2002 Dec;51 Suppl 3:S368-76. [PubMed:12475777 ]
Bataille D: [Molecular mechanisms of insulin secretion]. Diabetes Metab. 2002 Dec;28(6 Suppl):4S7-13. [PubMed:12703060 ]

Details

3. ATP-binding cassette sub-family C member 8

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inducer

General Function:: Sulfonylurea receptor activity
Specific Function:: Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release.
Gene Name:: ABCC8
Uniprot ID:: Q09428
Molecular Weight:: 176990.36 Da

References

Muller G, Hartz D, Punter J, Okonomopulos R, Kramer W: Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta. 1994 May 11;1191(2):267-77. [PubMed:8172912 ]
Kramer W, Muller G, Geisen K: Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res. 1996 Sep;28(9):464-8. [PubMed:8911984 ]
Kramer W, Muller G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, Summ HD: The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Diabetes Res Clin Pract. 1995 Aug;28 Suppl:S67-80. [PubMed:8529521 ]

Enzymes

Details

1. Cytochrome P450 2C9

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Steroid hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:: CYP2C9
Uniprot ID:: P11712
Molecular Weight:: 55627.365 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 13, 2005 07:24 / Updated on June 24, 2017 13:07

Get DrugBank to go!

Structure for DB00222 (Glimepiride)

Targets

References

References

References

Enzymes

References